Charles Schwab’s Gossamer Bio GOSS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$163K Sell
12,407
-6,469
-34% -$144K ﹤0.01% 3386
2026
Q1
$496K Sell
18,876
-2,196
-10% -$276K ﹤0.01% 3106
2025
Q4
$5.23M Sell
21,072
-548
-3% -$125K ﹤0.01% 2432
2025
Q3
$4.55M Buy
21,620
+1,352
+7% +$238K ﹤0.01% 2482
2025
Q2
$1.99M Buy
20,268
+6,031
+42% +$526K ﹤0.01% 2671
2025
Q1
$1.25M Sell
14,237
-1,288
-8% -$119K ﹤0.01% 2767
2024
Q4
$1.12M Buy
15,525
+174
+1% +$11.9K ﹤0.01% 2877
2024
Q3
$1.21M Sell
15,351
-419
-3% -$32.2K ﹤0.01% 2861
2024
Q2
$1.14M Buy
15,770
+110
+0.7% +$6.58K ﹤0.01% 2885
2024
Q1
$1.48M Buy
15,660
+412
+3% +$36.3K ﹤0.01% 2677
2023
Q4
$1.11M Buy
15,248
+1,740
+13% +$103K ﹤0.01% 2794
2023
Q3
$900K Buy
13,508
+8,148
+152% +$751K ﹤0.01% 2833
2023
Q2
$515K Sell
5,360
-424
-7% -$42.2K ﹤0.01% 3042
2023
Q1
$583K Sell
5,784
-992
-15% -$152K ﹤0.01% 2902
2022
Q4
$1.18M Buy
6,776
+149
+2% +$98.1K ﹤0.01% 2727
2022
Q3
$6.35M Buy
6,627
+1,659
+33% +$1.65M ﹤0.01% 2096
2022
Q2
$3.33M Sell
4,968
-126
-2% -$78.1K ﹤0.01% 2367
2022
Q1
$3.54M Buy
5,094
+213
+4% +$164K ﹤0.01% 2444
2021
Q4
$4.42M Buy
4,881
+99
+2% +$94.1K ﹤0.01% 2408
2021
Q3
$4.81M Buy
4,782
+253
+6% +$186K ﹤0.01% 2396
2021
Q2
$2.94M Buy
4,529
+529
+13% +$367K ﹤0.01% 2593
2021
Q1
$2.96M Sell
4,000
-215
-5% -$173K ﹤0.01% 2538
2020
Q4
$3.26M Buy
4,215
+7
+0.2% +$5.52K ﹤0.01% 2429
2020
Q3
$4.18M Buy
4,208
+133
+3% +$141K ﹤0.01% 2161
2020
Q2
$4.24M Buy
4,075
+984
+32% +$990K ﹤0.01% 2101
2020
Q1
$2.51M Buy
3,091
+56
+2% +$58.5K ﹤0.01% 2181
2019
Q4
$3.8M Buy
3,035
+52
+2% +$83.8K ﹤0.01% 2169
2019
Q3
$4.01M Buy
2,983
+1,637
+122% +$2.6M ﹤0.01% 2091
2019
Q2
$2.39M Buy
1,346
+280
+26% +$429K ﹤0.01% 2312
2019
Q1
$1.85M Buy
+1,066
New +$1.78M ﹤0.01% 2389

Other funds holding GOSS

Charles Schwab's GOSS Position: Q2 2026 in Review

Charles Schwab reduced its Gossamer Bio (GOSS) stake by 34% in Q2 2026, selling an estimated $144K and leaving 12,407 shares worth $163K. The position accounts for ﹤0.01% of the portfolio, ranked #3386.

Charles Schwab first reported a position in GOSS in Q1 2019 and has held it in 30 quarters since. The position peaked at $6.35M in Q3 2022. 166 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

  • Charles Schwab held 12,407 shares of Gossamer Bio worth $163K as of Q2 2026.
  • Charles Schwab sold 6,469 Gossamer Bio shares in Q2 2026, an estimated $144K.
  • Gossamer Bio made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3386 holding.
  • Charles Schwab first reported a position in Gossamer Bio in Q1 2019 and has held it in 30 quarters since.
  • Charles Schwab's Gossamer Bio position peaked at $6.35M in Q3 2022.
  • 166 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.